By continuing to use the site you agree to our Privacy & Cookies policy

Your browser seems to have cookies disabled. For the best experience of this website, please enable cookies in your browser.


Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


Anti-stroke drug may cut risk for 1.2 million people with AF

The first new and significant blood-thinning drug in 50 years is now available for people with irregular heartbeats and has been described as “very promising” for people at risk of stroke.

Pradaxa (dabigatran etexilate) can potentially cut stroke risk for the 1.2 million people in the UK with atrial fibrillation (AF).

Each year in the UK around 150,000 people have a stroke, of whom at least one in every six (15%) have AF.

The American College of Cardiology was told in April that Pradaxa can mean as much as a 39% stroke-risk reduction for some patients, and that the drug works better than the usual warfarin. Correct dosage of Pradaxa is also said to be easier to administer.

Stroke Association chief executive Jon Barrick said: “This new medication appears to be very promising.

“However, it’s important to note that it won’t be suitable for all, and every AF patient needs to be treated on a case-by-case basis to ensure that they receive the best possible treatment for them.”


Readers' comments (1)

Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!